The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
MMR vaccine and idiopathic thrombocytopaenic purpura
Open accessAbstract
AIMS: To estimate the relationship between idiopathic thrombocytopaenic purpura (ITP) and the measles, mumps and rubella (MMR) vaccination in children; calculating the relative risk estimate for ITP with in 6 weeks after MMR vaccination and the attributable risk of ITP within 6 weeks after MMR vaccination. METHODS: Using the General Practice Research Database we identified children with a first-time diagnosis of ITP from a base population of children aged less than 6 years between January 1988 and December 1999. After describing the characteristics of all the children identified with ITP, we focused on cases aged 13-24 months to perform a population-based, case-control analysis to estimate the relative risk of developing ITP within 6 weeks after MMR vaccination. We also calculated the risk of ITP attributable to the MMR vaccination. RESULTS: Sixty-three children with a first time diagnosis of ITP were identified; 23 cases were between 13 and 24 months old. The relative risk estimate for ITP within 6 weeks after MMR vaccination, compared to the combined group of unvaccinated children and children vaccinated with MMR more than 26 weeks previously was 6.3 (95% CI 1.3-30.1). The attributable risk of developing ITP within 6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations (95% confidence interval 21,300, 89,400). CONCLUSION: This study confirms the increased risk of ITP within 6 weeks after MMR vaccination. However, the attributable risk of ITP within 6 weeks after MMR vaccination is low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Lack of clarity over the vaccine exposure status of the controls made the results of the Black 2003 study difficult to interpret.”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as Black 2003
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moderate/unknown risk of bias: eight studies (Black 2003; Bremner 2005; Bremner 2007; DeStefano 2004; Ma 2005; Mrozek-Budzyn 2010; Ray 2006; Smeeth 2004).”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as Black 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Self-citationKaye, J. A., Melero-Montes, M. D. M., & Jick, H. (2001) · BMJ · doi:10.1136/bmj.322.7284.460 · Cited by 388
Jick, H., Terris, B. Z., Derby, L. E., & Jick, S. S. (1992) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2630010607 · Cited by 265
Short report: Idiopathic thrombocytopenic purpura and MMR vaccine
Miller, E. J. (2001) · Archives of Disease in Childhood · doi:10.1136/adc.84.3.227 · Cited by 228
The General Practice Research Database. Scientific and Ethical Advisory Group
Lawson, D. H. (1998) · QJM · doi:10.1093/qjmed/91.6.445 · Cited by 176
Beeler, J. A., Varricchio, F. E., & Wise, R. P. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199601000-00020 · Cited by 84
Jick, H. (1997) · The Lancet · doi:10.1016/s0140-6736(05)70451-7 · Cited by 81
Current topic: Idiopathic thrombocytopenic purpura
Bolton‐Maggs, P. H. B. (2000) · Archives of Disease in Childhood · doi:10.1136/adc.83.3.220 · Cited by 76
Jonville‐Béra, A. ‐., AUTRET, E., Galy-Eyraud, C., & Hessel, L. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199601000-00010 · Cited by 57
Recurrent Thrombocytopenic Purpura After Repeated Measles-Mumps-Rubella Vaccination
Vlacha, V., Forman, E. N., Miron, D., & Peter, G. (1996) · PEDIATRICS · doi:10.1542/peds.97.5.738 · Cited by 55
Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine
Ronchi, F., Cecchi, P., Falcioni, F., Marsciani, A., Minak, G., Muratori, G., Tazzari, P. L., & Beverini, S. (1998) · Archives of Disease in Childhood · doi:10.1136/adc.78.3.273 · Cited by 35
Haemophilus influenzae vaccine.
Jick, H., Withers, J. M., & Dean, A. D. (1995) · Europe PMC (PubMed Central) · Cited by 24
Chang, S.-S., Farrell, D. L., Dougan, K., & Kobayashi, B. (1996) · PubMed · Cited by 14
Mechanisms in childhood idiopathic thrombocytopenic purpura (ITP)
Winiarski, J. H. (1998) · Acta Paediatrica · doi:10.1111/j.1651-2227.1998.tb01235.x · Cited by 14
Mechanisms in childhood idiopathic thrombocytopenic purpura (ITP)
Winiarski, J. H. (1998) · Acta Paediatrica · doi:10.1080/080352598750030762 · Cited by 5
Research works printed but not linked: 2
- Lawson DH, 1998, General Prac Res Database QJM, 91, 445
- Jick H, 1995, Haemophilus influenza vaccine, Br J Gen Pract, 45, 107
Cited by
Sorted by citations
The ITP syndrome: pathogenic and clinical diversity
Cines, D. B., Bussel, J. B., Liebman, H. A., & Prak, E. T. L. (2009) · Blood · doi:10.1182/blood-2009-01-129155 · Cited by 809
“10 of 4090 patients with HD developed ITP after a median of 23 months (3-57), including 6 in remission(58).”
BackgroundVaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub3 · Cited by 372
Norton, A., & Roberts, I. A. G. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05809.x · Cited by 256
“Thrombocytopenia has been demonstrated following the measles, mumps and rubella (MMR) vaccination, with Black et al (2003) estimating the relative risk for ITP within 6 weeks after MMR vaccination to be 6Æ3 [95% confidence interval (CI) 1Æ3– 30Æ1] and the attributable risk of developing ITP within…”
BackgroundPathobiology of Secondary Immune Thrombocytopenia
Cines, D. B., Liebman, H. A., & Stasi, R. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.12.005 · Cited by 246
Vaccines for measles, mumps, rubella, and varicella in children
Pietrantonj, C. D., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub4 · Cited by 202
Metadata
- Authors
- Black, C., Kaye, J. A., & Jick, H.
- Affiliations
- Boston University (US)
- Corresponding author
- Black, Corri
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 55
- Issue
- 1
- Pages
- 107-111
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC1884189
- OpenAlex
- W1486224385
- Cited by
- 137
- References
- 14
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 2 · 2022: 10 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 7 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Novartis Farmacéutica
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- MMR vaccine, measles-mumps-rubella vaccination, vaccine adverse events, children, relative risk, attributable risk
- MeSH terms
- Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Risk Factors, Case-Control Studies, Purpura, Thrombocytopenic, Idiopathic, Measles-Mumps-Rubella Vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
